As has been widely reported in the IP and wider press, a major breakthrough was made at a political level on 29 June 2012 on the long-running EU Unitary Patent and Unified Patents Court dossier. Importantly, the agreement reached included a significant amendment to the previous proposals, whereby provisions would be deleted from the draft…
In 2007 in Nichia v Argos* the UK’s most senior full-time patents judge at the time, Jacob LJ, held that disclosure should no longer be available as a matter of course on standard issues such as obviousness in patent cases. This came as a breath of fresh air to many IP practitioners in the UK…
The following summarises another interesting decision for the rejuvenated Patents County Court which is continuing to flourish as a forum for smaller intellectual property disputes of all kinds. Merck is the proprietor of European Patent (EP (UK) 1 480 717) which, in relation to the product montelukast (Singulair, used for the treatment of adult and…
When does the demonstration of a model at a trade fair, or a similar limited availability of a product, constitute novelty-destroying prior disclosure? Although it will depend on the patent claims, the public’s opportunity to investigate the model may be important as demonstrated in the recent case of Wagner v Earlex*. As of the implementation…
Merck Sharp Dohme Corp. and Bristol-Myers Squibb Pharmaceuticals Limited v. Teva Pharma B.V. and Teva UK limited On 15 March 2012, the High Court in England and Wales delivered some useful guidance on when a patentee can obtain an interim injunction in a pharmaceutical patent infringement action. The case was Merck Sharp Dohme Corp. and…
Last April we reported the case of Gedeon Richter plc v Bayer Schering Pharma AG [2011] EWHC 583 (Pat), concerning immediate release formulations of a combination contraceptive product containing the steroidal hormones drospirenone and ethinylestradiol. We can now report the decision of the Court of Appeal in this case (handed down on 7 March 2012)…
The English High Court has upheld the decision of the UK Intellectual Property Office to refuse the grant of a patent for the treatment of inflammatory bowel disease (IBD) with zinc (El-Tawil v The Comptroller General of Patents [2012] EWHC 185 (Ch)). Although the case does not break new ground, it provides a useful review…
On 20 January 2012 the Court of Appeal in England heard the case of Apimed Medical Honey v Brightwake Limited [2012] EWCA Civ 5. Apimed owned European Patent (UK) 1,237,561 (‘the Patent’) for an invention of “Medical dressings comprising gelled honey” and this was held invalid for obviousness at first instance in the Patent’s County…
Although a number of issues were raised as to the validity of two patents in the recent Omnipharm v Merial[2001] EWHC 3393 (Pat) case, the most interesting feature of the case was the judge’s approach to the question of inventive step. The case focussed in particular on the role of the doctrine of “obvious to…
The English High Court has recently ruled on the appropriateness of staying validity and infringement proceedings pending a Technical Board of Appeal (“TBA”) decision of the European Patent Office (“EPO”), and on using disclosed documents in parallel foreign proceedings. The parties involved have had a number of skirmishes recently in various courts throughout the world….
